Business

California-based Impax Pharmaceuticals has acquired exclusive US rights to several dosage forms of Zomig zolmitriptan, including the nasal spray formulation, from AstraZeneca. Zomig nasal spray is approved in the US for the treatment of migraine… Read more . . .

After having its first offer rejected by ISTA Pharmaceuticals, and after ISTA indicated that an increased offer was still insufficient, Valeant Pharmaceuticals has withdrawn its offer of $7.50 per share a day before its announced… Read more . . .

A company called Rapid Fire Marketing says that its subsidiary Medical Cannabis Management is launching a tetrahydrocannabinol (THC) e-cigarette in the US immediately and will follow with a second-generation device in 30-60 days. The device,… Read more . . .

Spanish pharmaceutical company Almirall and Belgian biotech Galapagos have entered into a three-year agreement “aimed at delivering drug development candidates directed to a key respiratory target of interest to Almirall.” According to the companies, the… Read more . . .

Aptar Pharma has opened a new manufacturing facility in Rabale, Navi Mumbai, India, where it will produce the DF30 metering valve for pressurized metered dose inhalers (MDIs) and spray pump assemblies for nasal spray delivery.… Read more . . .

Takeda Pharmaceutical has announced that it will lay off approximately 2,800 employees — 2,100 in Europe and 700 in the US — as it realigns to accommodate its 2011 acquisition of Nycomed. Nycomed’s products include… Read more . . .

After the rejection of its last offer in December, Valeant Pharmaceuticals says that it has increased its offer for ISTA to $7.50 per share from $6.50 and adds that it has informed ISTA that the… Read more . . .

A new report available from BCC Research projects a compound annual growth rate (CAGR) of 14.3% for the respiratory drug delivery technologies market, meaning that the global market would approximately double to $44 billion by… Read more . . .

According to an interim management statement released by Vectura, the company anticipates a cut R&D expenditures by £1m for the fiscal year ending March 31 2012 and expects additional cuts for FY2013. The company said,… Read more . . .